News
AARD
1.040
-9.57%
-0.110
RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)
TipRanks · 1d ago
Weekly Report: what happened at AARD last week (1109-1113)?
Weekly Report · 2d ago
Analysts Offer Insights on NA Companies: Mobility Global Inc (MBGL) and Aardvark Therapeutics, Inc. (AARD)
TipRanks · 2d ago
Aardvark Therapeutics GAAP EPS of -$0.88
Seeking Alpha · 5d ago
Aardvark Therapeutics reports Q3 EPS (88c), consensus (75c)
TipRanks · 5d ago
*Aardvark Therapeutics 3Q Research & Development $15.7M >AARD
Dow Jones · 5d ago
*Aardvark Therapeutics 3Q Loss/Shr 88c >AARD
Dow Jones · 5d ago
Press Release: Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 5d ago
Press Release: Aardvark Therapeutics Reports -2-
Dow Jones · 5d ago
Aardvark Therapeutics Q3 EPS $(0.88) Misses $(0.77) Estimate
Benzinga · 5d ago
Weekly Report: what happened at AARD last week (1102-1106)?
Weekly Report · 11/09 10:24
Aardvark Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
TipRanks · 11/04 21:22
Weekly Report: what happened at AARD last week (1026-1030)?
Weekly Report · 11/02 10:24
Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals
NASDAQ · 10/30 16:56
Aardvark Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 10/27 19:29
Aardvark Therapeutics Price Target Cut to $10.00/Share From $19.00 by Jones Trading
Dow Jones · 10/27 19:29
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/27 17:05
Aardvark Therapeutics price target lowered to $10 from $19 at Jones
TipRanks · 10/27 08:40
Aardvark Therapeutics downgraded to Perform from Outperform at Oppenheimer
TipRanks · 10/26 17:40
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/26 17:05
More
Webull provides a variety of real-time AARD stock news. You can receive the latest news about Aardvark Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).